Allianz Asset Management
ABCL icon

Allianz Asset Management’s AbCellera Biologics ABCL Stock Holding History

Allianz Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,622
Closed -$60.5K – 1986
2025
Q1 		$60.5K Buy
25,622
+14,044
+121% +$40.3K ﹤0.01% 2189
2024
Q4 		$32.6K Sell
11,578
-8,015
-41% -$22.3K ﹤0.01% 2173
2024
Q3 		$50.9K Buy
19,593
+6,806
+53% +$18.9K ﹤0.01% 2139
2024
Q2 		$37.9K Buy
12,787
+2,394
+23% +$9.06K ﹤0.01% 2079
2024
Q1 		$47.1K Buy
+10,393
New +$53K ﹤0.01% 1989
2022
Q3 		– Sell
-10,822,530
Closed -$115M – 1866
2022
Q2 		$115M Sell
10,822,530
-335,515
-3% -$2.84M 0.11% 206
2022
Q1 		$109M Sell
11,158,045
-6,965
-0.1% -$65.9K 0.08% 262
2021
Q4 		$160M Sell
11,165,010
-693,786
-6% -$10.5M 0.11% 202
2021
Q3 		$238M Buy
11,858,796
+1,929,092
+19% +$34.1M 0.18% 122
2021
Q2 		$218M Buy
+9,929,704
New +$274M 0.18% 116

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Allianz Asset Management's ABCL Position: Q2 2025 in Review

Allianz Asset Management sold out of AbCellera Biologics (ABCL) in Q2 2025, closing a stake of 25,622 shares — an estimated $60.5K sold.

Allianz Asset Management first reported a position in ABCL in Q2 2021 and held it in 10 quarters. The position peaked at $238M in Q3 2021. 128 funds tracked by Wall St. Rank hold ABCL as of Q2 2025.

  • Allianz Asset Management reported no remaining AbCellera Biologics position as of Q2 2025 after selling out during the quarter.
  • Allianz Asset Management sold 25,622 AbCellera Biologics shares in Q2 2025, an estimated $60.5K.
  • Allianz Asset Management first reported a position in AbCellera Biologics in Q2 2021 and held it in 10 quarters.
  • Allianz Asset Management's AbCellera Biologics position peaked at $238M in Q3 2021.
  • 128 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2025.

Based on Allianz Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.